Introduction {#Sec1}
============

Adult onset cerebellar ataxia poses a considerable diagnostic challenge. Initial investigations focus on detecting degenerative, toxic, structural and inflammatory etiologies which together underlie around a third of cases \[[@CR1]\]. Thereafter, molecular investigations for a monogenic basis of disease are often undertaken despite 80 % of patients having no relevant family history \[[@CR2]\].

Current molecular investigations for sporadic cases echo that of familial forms, beginning with testing for trinucleotide repeat disorders, such as the spinocerebellar ataxias (SCA1, 2, 3, 6, 7 and 17), dentatorubral pallidoluysian atrophy (DRPLA) and Friedreich's ataxia (FDR) in most centres \[[@CR1]\]. However, this approach fails to identify a molecular diagnosis in 87--98 % of late onset sporadic cases \[[@CR1], [@CR3]\], and subsequent investigations are undertaken on a gene-by-gene basis, often at considerable time and expense.

The difficulty in establishing monogenic forms of disease using this approach is increasingly challenging given that at least 60 causative ataxia genes are reported \[[@CR4]\]. Recent studies have therefore utilized next generation sequencing focusing on infantile or juvenile onset cases \[[@CR5]\], or adult onset ataxia with a demonstrable family history \[[@CR4]\]. Only two studies have described sub-sets of patients with sporadic onset adult disease, despite it being a major form of ataxia, and suggested that a molecular diagnosis can be reached in \~10 % of cases \[[@CR4], [@CR6]\]. Given this, we applied whole exome sequencing to a cohort of individuals with sporadic late onset ataxia.

Methods {#Sec2}
=======

Unrelated individuals with sporadic ataxia beginning at 30 years of age or over were identified from routine referrals to our regional neurogenetic service, in Newcastle upon Tyne, England.

Acquired causes of ataxia were excluded and all participants had negative genetic testing for SCA 1, 2, 3, 6, 7, 17, *DRPLA* and Friedreich's Ataxia (FA). In addition, all adult males had negative *FMR1* testing.

Blood genomic DNA was fragmented, exome enriched and sequenced (Nextera Rapid Exome Capture 37 Mb and HiSeq 2000, 100 bp paired-end reads). In-house bioinformatic analysis included alignment to UCSC hg19, using BWA as aligner and GATK to detect SNV and INDELS across all samples using standard filtering parameters according to GATK Best Practise Recommendations \[[@CR7]\] (see supplementary methods). Further analysis was performed on variants with a minor allele frequency \<0.005 in several reference databases and 302 unrelated in-house controls (see supplementary methods). Rare heterozygous, homozygous and compound heterozygous variants were defined, and protein altering and/or putative 'disease causing' mutations as predicted by at least three out of four software programmes were included. Pathogenicity was defined in accordance with American College of Medical Genetic guidelines (see supplementary methods). Genes known or suggested to cause ataxia as a primary or secondary phenotype in humans from two suggested clinical panels \[[@CR4], [@CR8]\] together with additional genes in which ataxia may result as part of the phenotype (list-supplementary methods) were assessed for variants according to the above criteria, and confirmed by Sanger sequencing (supplementary methods).

Variants were defined using a priori criteria: (1) confirmed pathogenic: dominant disorders*---*variant previously shown to cause ataxia in humans; recessive disorders*---*either 2 variants previously shown to cause ataxia in humans; or 1 pathogenic variant with a second variant predicted to affect protein function by at least 3 of 4 prediction algorithms (SIFT, Polyphen2, Mutation Taster, LRT), or through frameshift or truncation. (2) Probable pathogenic: dominant and recessive disorders---variants in known genes causing ataxia in humans and predicted to affect protein function by at least three of four prediction algorithms; (3) uncertain significance: dominant and recessive disorders---variants predicted to affect protein function with weak evidence that gene alteration causes ataxia in humans.

The study was granted ethical approval from a Research Ethics Committee based in the North of England.

Results {#Sec3}
=======

Population {#Sec4}
----------

Twelve Caucasian individuals of British origin (5 male) with no known consanguinity were included (Table [1](#Tab1){ref-type="table"}). Mean age at disease onset was 46.7 years (SD 11; range 30--70 years). Mean disease duration was 16.6 years (SD 6.9; range 6--30 years). For one patient, the disease duration fell within the range expected for multi-system atrophy \[[@CR9]\]. This patient had a normal DaTscan and autonomic function tests. Three individuals had CSF examination with negative oligoclonal bands. Five had nerve conduction studies; two of which were abnormal. Detailed clinical features and the results of clinical investigations are shown in Table [1](#Tab1){ref-type="table"}.Table 1Clinical features of the 12 patients in the cohortPatient no., sexAge (years)Age onset (years)Disease duration (years)Presenting symptomGait ataxiaLimb ataxiaOcular signsAdditional neurological featuresOther featuresMRILPNCS/EMGOther investigationsMuscle biopsyOther negative molecular investigations1, F634023Slowly progressive midline and appendicular ataxic syndrome+++++Early CPEO\
Dysmetric pursuit\
Broken saccadesDysphagia, spastic bladder\
Lower limb spasticityNoneCANormal\
−OCBBilateral CTS (CTS study only)Normal IHC\
No mtDNA deletions*FMR1*2, F473017Slowly progressive spastic ataxic syndrome++ (Fr)+CPEO\
Temporal optic disc pallor\
Jerky pursuit\
Hypometric saccadesSpastic lower limbs\
Brisk reflexesNoneMild CANormal\
−OCBNDMild fibre size variation\
Low Q10Nil3, F574512Ataxia developed aged 45+++++Slow saccadesEpilepsy aged 7NoneCA and parieto-occipital atrophyNDNormalND*FMR1*4, F634023Slowly progressive midline cerebellar ataxia+++GENTLE with ongoing infrequent focal seizures, no treatmentCataracts (age 62)CANDNDND*POLG*\
*MT*-*ATP6 &* 85, F553520Slowly progressive spastic ataxic syndrome+++ (WhC)++Jerky pursuit\
GEN\
Hypometric saccadesNeurogenic bladder\
Spastic ataxic gait\
Brisk reflexes\
Positive BabinskiNoneCANDNDND*SPG7*6, F76706Progressive midline and appendicular ataxia+++++GEN\
Up and down beat nystagmusOrthostatic tremor\
Brisk reflexesNoneMild CANDND−DaTNormal IHC\
No mtDNA deletions*MT*-*ATP 6 & 8*7, M716011Slowly progressive midline ataxia+−Jerky ocular pursuit\
GENNoneNoneCANDNormalND*SPG7*\
*MT*-*ATP 6 & 8*8, M58508Midline ataxia+++RAPD\
OA\
Jerky pursuit\
GENCongenital hearing loss\
Early dysphagia\
AreflexiaNoneCANDSANNormal IHC\
No mtDNA deletions\
Normal Q10*POLG*\
*WFS1*\
*OPA1*\
*MT*-*ATP 6 & 8*9, M704030Pure midline ataxia+ (stick)−NoneNoneNoneCANDNDNormal IHC\
Normal RCESCA12\
mt.DNA LR-PCR10, M594415Pure midline ataxia++++NoneProminent dysarthria, choking\
Brisk reflexesNoneCANDNDNormal Q10*SPG7*\
SCA8\
SCA1211, F654712Pure midline ataxia+++ (WhC)+Oscillopsia\
Jerky pursuits\
Horizontal nystagmus\
Hypometric saccadesDorsal root ganglionopathy\
Neurogenic bladder\
Distal wasting and weakness\
AreflexiaCataract, diabetes and short statureMild CA; high signal C3, 4 posterior columns; thin cord−OCBDRGND*POLG*\
*SPG7*\
*POLG2*\
*PEO1*\
*ANT1*\
mt.DNA LR-PCR12, M836023Midline ataxia\
Early alcohol sensitivity++ (stick)+Jerky pursuit\
Coarse phasic nystagmus\
Normal saccadesNoneNoneMild CANDNDPatient declinedNilPresence or absence of symptoms are indicated by + or − symbol, respectively*AFTs* autonomic function tests, *CA* Cerebellar atrophy, *CPEO* chronic progressive external ophthalmoplegia, *CTS* carpal tunnel syndrome, *CVD* cerebrovascular disease, *DRG* dorsal root ganglionopathy, *Fr* Frame, *GEN* gaze evoked nystagmus, *IHC* immunohistochemistry, *ND* not done, *OA* optic atrophy, *OCB* oligoclonal bands, *PV* periventricular, *RAPD* relative afferent pupillary defect, *RCE* respiratory chain enzyme, *SVD* small vessel disease, *TLE* temporal lobe epilepsy, *WhC* wheelchair, *WM* white matter

Diagnosis {#Sec5}
---------

We identified previously described pathogenic mutations in four of the 12 (33 %) patients in our cohort. All were present on confirmatory Sanger sequencing. No probable pathogenic variants were identified and variants of uncertain significance were found in an additional two cases (17 %). Findings are summarised in Table [2](#Tab2){ref-type="table"}.Table 2Genetic variants of interest identified in the 12 patientsPathogenic variantsPtGeneModelExome seq identified variant (1)rs\#MAF variant (1)Exome seq identified variant (2)rs\#MAF variant (2)Variant pathogenicity predictionESP65001000 gESP65001000 g1*SPG7*ARc.1529C\>T\
p. Ala510Valrs617553200.0034630.0014c. 1053dupC\
p. Gly352fsNA00(1) D:D:D:D\
(2) NA2*SPG7*ARc.1529C\>T\
p. Ala510Valrs617553200.0034630.0014c.233T\>A\
p. Leu78\*rs1219183580.0000770(1) D:D:D:D\
(2) Pathogenic3*ANO10*ARc.1843G\>A\
p. Asp615Asnrs1380003800.0002310.0005c. 132_133insT\
p. Asp45fsNA00(1) D:D:D:P\
(2) NA4*SYNE1*ARc.9148C\>G\
p. Leu3050Valrs1173607700.0023070.0018c.1762delC\
p. Leu588fsNA0.0034350(1) D:D:D:D\
(2) NAVariants of uncertain significance5*SLC33A1*ADc.433G\>A\
p. Gly145Serrs1382832290.0024610.0009NANANAD:D:D:D6*PLEKHG4*ADc.2251G\>A\
p. Asp751AsnNA0.0000770NANANAD:D:N:DConfirmed pathogenic: dominant disorders---variant previously shown to cause ataxia in humans; recessive disorders---either 2 variants previously shown to cause ataxia in humans; or 1 pathogenic variant with a second variant predicted to affect protein function by at least 3 of 4 prediction algorithms (SIFT, Polyphen2, Mutation Taster, LRT), through frameshift or truncation. Variants of uncertain significance: dominant and recessive disorders---variants predicted to affect protein function with weak evidence that gene alteration causes ataxia in humans*D* pathogenic or deleterious, *P* polymorphism, *NA* not applicable *N* neutral (frameshift mutations considered pathogenic)

Discussion {#Sec6}
==========

We identified confirmed or probable pathogenic variants causing sporadic late onset ataxia in four patients (33 %) in our cohort. These findings are comparable to childhood/adolescent ataxia using targeted sequencing panels (40 %) \[[@CR4]\] and whole exome sequencing (27 %) \[[@CR5]\]. They are also significantly higher than previous data for adult onset cases using either panels or whole exome (both \~10 %) \[[@CR4], [@CR6]\].

We detected pathogenic variants in *SPG7, SYNE1 and ANO10* (previously published by Balreira et al. \[[@CR10]\]). Fogel et al. \[[@CR6]\] also identified pathogenic variants in these genes (*SPG7* (*n* = 2), *SYNE1* (*n* = 3) and *ANO10* (*n* = 1). The clinical features of these patients appear relatively homogenous between their and our study, with pure cerebellar ataxia beginning above the age of 40 for *ANO10* and *SYNE1* cases, and a more heterogeneous age of onset (\<20--50) with additional neurological features including spasticity and a polyneuropathy in *SPG7* cases \[[@CR6]\]. Therefore, pathogenic mutations in these genes appear to be an important and frequently identified cause of late onset sporadic ataxia.

We used whole exome sequencing (WES) rather than targeted next generation 'panels', and it remains a contentious issue as to which is more appropriate in the investigation of neurogenetic disorders. WES enables greater genome coverage, and hence detection of pathogenic mutations in genes not considered as having ataxia as a primary phenotype. Our results highlight this as *SPG7* was not covered by one ataxia panel \[[@CR4]\], *SYNE1* by another \[[@CR8]\], and *ANO10* was not included in either panel. WES however, may result in detection of unexpected findings such as pathogenic mutations predisposing to cancer or neurodegenerative disease, which must be considered and included in appropriate consent procedures. It must also be noted that neither WES nor targeted panels are appropriate to screen for genomic rearrangements or trinucleotide repeat sequences.

Determining pathogenicity can be challenging for heterozygous variants without a family history of disease and additional living family relatives for segregation analysis. In our cohort, we found heterozygous variants in *SLC33A1* and *PLEKHG4* in single cases (Table [2](#Tab2){ref-type="table"}). Heterozygous mutations in *SLC33A1* have been associated with spastic paraplegia (SPG42) with ataxia in a single family, and likewise, missense mutations in *PLEKHG4* have been implicated in dominant late onset forms of spinocerebellar ataxia in Japanese individuals. Despite the rarity and putative pathogenicity of the variants in our patients, the lack of data to test segregation makes attributing pathogenicity difficult. As NGS begins to develop larger variant datasets in rare diseases it is vital to share such data through collaborative projects which may aid pathogenicity confirmation through the identification of the same or related variants in unrelated families with a similar phenotype.

In conclusion, we have demonstrated that application of WES to a cohort of unrelated individuals following exclusion of common trinucleotide repeat disorders establishes a molecular cause of disease in a third of cases. These findings have significant implications for clinical practise.
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